ArticleAnimal models and experimental medicine2026
UHPLC-MS based metabolomics study of the ErZhi formula on skeletal muscle against osteosarcopenia focusing on energy metabolism.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe ErZhi formula (EZF) exhibits sound therapeutic effects on osteosarcopenia (OS). However, EZF's therapeutic effects on skeletal muscles are rarely reported. This study explored the mechanism of EZF in skeletal muscle during OS by integrating energy metabolism and metabolomics.
methodsAfter an ovariectomized rat model was established for 4 weeks, the rats were subjected to a 12-week intervention of EZF and alendronate. The rats' body weight, gastrocnemius muscle mass, degree of myofiber fibrosis, and myofiber cross-sectional area (CSA) were measured to evaluate the pathological state of the gastrocnemius muscle. The mitochondrial membrane potential and reactive oxygen species (ROS) levels were detected to assess mitochondrial function. Then, energy metabolite analysis and metabolomics were performed on the gastrocnemius muscle.
resultsCompared to the model group, EZH increased CSA by 5.58% and decreased myofiber fibrosis by 15.11%. Notably, compared to the model group, EZH exhibited a 52.66% increase in mitochondrial membrane potential and a 44.32% reduction in ROS levels. Starch and sucrose metabolism, insulin secretion, insulin resistance, and galactose metabolism were the most significantly affected pathways in energy metabolism. Thirty-five differential metabolites were found in the metabolomics of the gastrocnemius muscle, and EZF could effectively inhibit the sphingolipid metabolism pathway. Correlation analysis identified 13 differential metabolites that were significantly associated with skeletal muscle mass, ROS production, muscle fibrosis, and mitochondrial function, suggesting that these metabolites may play important roles in the progression of skeletal muscle lesions.
conclusionsEZF alleviates OS by regulating skeletal muscle physiological indicators, mitochondrial function, and energy metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.